Allogene Therapeutics, Inc. received an amended Schedule 13G filing reporting the beneficial ownership of its Common Stock by multiple Frazier Life Sciences investment entities and two individuals. The filing states that Frazier Life Sciences Public Fund, L.P. directly holds 19,445,046 shares of Common Stock, representing 5.6% of the class, based on 345,154,561 shares outstanding as of May 11, 2026.
Additional Frazier Life Sciences funds directly hold 306,906, 753,251, and 1,941,465 shares, with related ownership percentages of 0.1%, 0.2%, and 0.6%, respectively. James N. Topper and Patrick J. Heron share voting and investment power over the 306,906 shares held by Frazier Life Sciences X, L.P., while the filing includes customary disclaimers that it does not constitute an admission of beneficial ownership beyond what is specifically described.
Positive
None.
Negative
None.
Key Figures
FLSPF Shares Owned:19,445,046 sharesFLSPF Ownership Percentage:5.6%Shares Outstanding:345,154,561 shares+3 more
6 metrics
FLSPF Shares Owned19,445,046 sharesCommon Stock directly held by Frazier Life Sciences Public Fund, L.P.
FLSPF Ownership Percentage5.6%Percent of Allogene Common Stock class held by FLSPF
Shares Outstanding345,154,561 sharesAllogene Common Stock outstanding as of May 11, 2026 per Form 10-Q
FLS X Shares Owned306,906 sharesCommon Stock directly held by Frazier Life Sciences X, L.P. (0.1%)
FLS XI Shares Owned753,251 sharesCommon Stock directly held by Frazier Life Sciences XI, L.P. (0.2%)
FLS XII Shares Owned1,941,465 sharesCommon Stock directly held by Frazier Life Sciences XII, L.P. (0.6%)
"the beneficial owner of any securities covered by this /A"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
shared voting powerregulatory
"6 | Shared Voting Power 19,445,046.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerregulatory
"8 | Shared Dispositive Power 19,445,046.00"
Schedule 13Gregulatory
"for the purposes of Section 13(d) and/or Section 13(g) of the Act"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
CUSIP No.financial
"CUSIP No.: 019770106"
FAQ
What ownership stake in Allogene Therapeutics (ALLO) does Frazier Life Sciences Public Fund report?
Frazier Life Sciences Public Fund, L.P. reports 19,445,046 shares of Allogene Common Stock, representing 5.6% of the outstanding class. This percentage is based on 345,154,561 shares outstanding as of May 11, 2026, per Allogene’s Form 10-Q.
How many Allogene (ALLO) shares are outstanding for the percentage calculations in this Schedule 13G/A?
The reported ownership percentages are based on 345,154,561 shares of Allogene Common Stock outstanding as of May 11, 2026. That share count comes from Allogene’s Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
What Allogene (ALLO) holdings are reported by other Frazier Life Sciences funds in this filing?
Frazier Life Sciences X, XI, and XII funds report 306,906, 753,251, and 1,941,465 Allogene shares, respectively. These positions correspond to ownership of 0.1%, 0.2%, and 0.6% of the outstanding Common Stock, using the same 345,154,561-share base.
What role do James N. Topper and Patrick J. Heron have in the Allogene (ALLO) stake reported?
James N. Topper and Patrick J. Heron share voting and investment power over 306,906 Allogene shares held by Frazier Life Sciences X, L.P.. The filing notes these shares are directly held by that fund, with Topper and Heron as members of its general partner FHMLS X, L.L.C.
Does the Schedule 13G/A for Allogene (ALLO) attribute sole or shared voting power to the Frazier entities?
The Frazier entities report 0 shares with sole voting or dispositive power and only shared voting and dispositive power over their Allogene holdings. For example, Frazier Life Sciences Public Fund shows 19,445,046 shares with shared voting and shared dispositive power.
What disclaimers about beneficial ownership appear in the Allogene (ALLO) Schedule 13G/A?
The filing states that, except as specifically described, it should not be construed as an admission that any Reporting Person is the beneficial owner of the securities reported or a member of a “group” for Section 13(d) or 13(g) purposes.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Allogene Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
019770106
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Frazier Life Sciences Public Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
19,445,046.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
19,445,046.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
19,445,046.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.6 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
FHMLSP, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
19,445,046.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
19,445,046.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
19,445,046.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.6 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
FHMLSP, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
19,445,046.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
19,445,046.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
19,445,046.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.6 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Frazier Life Sciences X, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
306,906.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
306,906.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
306,906.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.1 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
FHMLS X, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
306,906.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
306,906.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
306,906.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.1 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
FHMLS X, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
306,906.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
306,906.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
306,906.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.1 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Frazier Life Sciences XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
753,251.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
753,251.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
753,251.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
FHMLS XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
753,251.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
753,251.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
753,251.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
FHMLS XI, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
753,251.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
753,251.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
753,251.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Frazier Life Sciences XII, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,941,465.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,941,465.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,941,465.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
FHMLS XII, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,941,465.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,941,465.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,941,465.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
FHMLS XII, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,941,465.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,941,465.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,941,465.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
James N. Topper
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
306,906.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
306,906.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
306,906.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.1 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P.
The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Patrick J. Heron
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
306,906.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
306,906.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
306,906.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.1 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P.
The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Allogene Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
210 East Grand Avenue, South San Francisco, CA, 94080.
Item 2.
(a)
Name of person filing:
The entities and persons filing this statement (collectively, the "Reporting Persons") are:
Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P.
FHMLSP, L.L.C.
Frazier Life Sciences X, L.P. ("FLS X")
FHMLS X, L.P.
FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
Frazier Life Sciences XII, L.P. ("FLS XII")
FHMLS XII, L.P.
FHMLS XII, L.L.C.
James N. Topper ("Topper")
Patrick J. Heron ("Heron")
(b)
Address or principal business office or, if none, residence:
The address of the principal place of business for each of the Reporting Persons is:
c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite 200B
Palo Alto, CA 94304
(c)
Citizenship:
The information contained in row 4 of each Reporting Person's cover page to this Schedule 13G/A is incorporated by reference.
(d)
Title of class of securities:
Common Stock, $0.001 par value per share
(e)
CUSIP No.:
019770106
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
FLSPF directly holds 19,445,046 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF.
FLS X directly holds 306,906 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X.
FLS XI directly holds 753,251 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI.
FLS XII directly holds 1,941,465 shares of Common Stock. FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII.
Except as specifically stated herein, the filing of this Schedule 13G/A shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13G/A or a member of a "group" with any other person.
(b)
Percent of class:
The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Frazier Life Sciences Public Fund, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:
08/14/2026
FHMLSP, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:
08/14/2026
FHMLSP, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:
08/14/2026
Frazier Life Sciences X, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:
08/14/2026
FHMLS X, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:
08/14/2026
FHMLS X, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS X, L.L.C.
Date:
08/14/2026
Frazier Life Sciences XI, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:
08/14/2026
FHMLS XI, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:
08/14/2026
FHMLS XI, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:
08/14/2026
Frazier Life Sciences XII, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date:
08/14/2026
FHMLS XII, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
Date:
08/14/2026
FHMLS XII, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XII, L.L.C.
Date:
08/14/2026
James N. Topper
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026
Date:
08/14/2026
Patrick J. Heron
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, Attorney-in-Fact for Patrick Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026
Date:
08/14/2026
Exhibit Information
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G filed on April 23, 2026)
